SkinBioTherapeutics (SBTX) | LSE:SBTX
Months after a fabricated-revenue scandal forced a restatement of its accounts, SkinBioTherapeutics shares are still under pressure, with a shrinking cash pile now adding to the list of investor concerns.
What happened
SkinBioTherapeutics (LSE:SBTX) shares were sharply lower on 13 August 2026, changing hands around 9.0p, down roughly 7.7% on the day, according to London Stock Exchange pricing data. That leaves the AIM-quoted skin-health and microbiome biotech with a Market Capitalisation of about £23 million, near the bottom of a 52-week range that has stretched from 22p to 5.2p.
There is no single fresh announcement dated 13 August that obviously explains the fall; trading in the shares is thin, with roughly 400,000 shares changing hands and a wide bid-offer spread, which can exaggerate day-to-day moves in small-cap names. The bigger story is one investors have been digesting for months: a former chief executive fabricated £0.77 million of Royalty revenue, triggering a forensic investigation, a trading suspension, restated accounts and a boardroom clear-out.
That saga culminated in half-year results and restated full-year figures published on 8 June 2026, and the aftershocks - particularly a steep fall in cash reserves - appear to still be weighing on sentiment as the shares remain well below levels seen before the scandal broke in February 2026.
Latest company news
On 8 June 2026, SkinBioTherapeutics published its half-year report for the six months to 31 December 2025 alongside restated results for the year ended 30 June 2025, ending an AIM suspension that had been in place since around 1 April 2026. Trading resumed at 7:30am that day.
The saga began on 16 February 2026, when the board announced that chief executive Stuart Ashman had resigned after an internal review found he had misrepresented material information to the board, auditors and advisers - specifically inflating accrued royalty income by £770,000 in the FY25 accounts. Shares fell sharply that day as the scale of the issue emerged, and non-executive chair Martin Hunt stepped in as executive chair on an interim basis.
An independent forensic investigation by FRP Advisory followed, delaying the interim results and prompting the AIM suspension from around 1 April 2026. FRP's conclusions, published with the June results, found the supporting documentation for the royalty accrual had been fabricated by the former CEO, with no evidence implicating anyone else, and no issues identified with the company's cash balances beyond that item. The probe did, however, flag corporate governance weaknesses, and additional adjustments were made for Bonus and consultancy payments to directors that had been recognised in the wrong periods.
As part of the fallout, Martin Hunt and non-executive director Dr Cathy Prescott voluntarily repaid a combined £0.23 million of bonuses and are stepping down from the board. Rachel Parsonage was appointed interim chief executive in March 2026, Alyson Levett became interim chair and led the investigation oversight, and finance director Emily Bertram was promoted to the board as CFO. A new auditor has also been appointed, and the company is pursuing recovery of roughly £0.7 million of investigation costs.
Financial position
Restated FY25 Revenue (year to 30 June 2025) came in at £3.87 million, down from the originally reported £4.64 million once the fabricated royalty accrual was stripped out. The restated operating loss widened to £2.13 million from £1.12 million as originally reported, and the EBITDA loss for the year increased to £1.40 million from £0.41 million. The company said cash balances themselves were unaffected by the restatement, standing at £4.78 million at 30 June 2025.
For the more recent HY26 period (six months to 31 December 2025), revenue rose 37.4% year-on-year to £2.17 million from £1.58 million, with gross Margin broadly maintained at around 55.6%. The operating loss narrowed slightly to £1.00 million from £1.03 million a year earlier. Growth was driven by a full six-month contribution from the Bio-Tech Solutions business, steady Dermatonics podiatry sales, and early licensing income alongside AxisBiotix listings in more than 180 Superdrug stores.
The more striking figure is cash. The company held £3.1 million at 31 December 2025, but this had fallen to £1.5 million by 31 May 2026 - a sizeable reduction over five months that reflects both ongoing operating losses and roughly £0.7 million of investigation-related costs. Directors have confirmed a going-concern basis after reviewing budgets for the next 12 months, but the trajectory of cash consumption relative to a sub-£25 million market cap is one investors will be watching closely for signs of a future fundraise.
Why the shares may be under pressure
Several factors, rather than any single trigger, appear to be weighing on sentiment. First, the reputational and governance damage from the fabricated-revenue episode has not fully unwound; investors typically Demand a higher risk premium - and a lower rating - for companies that have suffered an accounting scandal, even after remedial action.
Second, the sharp reduction in cash from £3.1 million to £1.5 million between December 2025 and May 2026 raises the prospect of further dilution if the company needs to raise fresh Equity to fund operations, particularly given continuing operating losses. Third, thin Liquidity in the stock - only a few hundred thousand shares typically trade daily - means moves of several percent can occur without a specific new catalyst, amplifying both up and down swings.
There is no verified evidence tying the 13 August move to a specific new disclosure; the pattern is consistent with a small, thinly traded stock still working through the consequences of a governance crisis rather than a fresh company-specific shock.
Bull case
Underlying trading has continued to grow through the crisis: HY26 revenue rose 37.4% and gross margins held above 55%, with the operating loss narrowing slightly year-on-year. Management points to genuine commercial momentum - AxisBiotix's expansion into Superdrug, steady Dermatonics podiatry sales, and Bio-Tech Solutions now contributing for a full period after its earlier acquisition.
The company has also taken visible steps to draw a line under the scandal: a new interim CEO and chair, a promoted CFO, a new auditor, strengthened internal controls, and voluntary repayment of bonuses by departing directors. If the board delivers the promised updated market guidance later in 2026 and demonstrates continued organic growth without further governance surprises, some of the discount currently applied to the shares could unwind.
Bear case
The most immediate risk is cash runway. With just £1.5 million on the Balance Sheet as of 31 May 2026 against continuing operating losses, the company may need to raise additional capital, which would likely dilute existing shareholders given the depressed share price and small market capitalisation.
Governance risk also lingers - the FRP investigation centred on one individual, but the episode exposed weaknesses in financial controls that will take time to rebuild credibility around. Legal action to recover roughly £0.7 million of investigation costs adds uncertainty and potential further costs. More broadly, SkinBioTherapeutics remains a small, loss-making biotech reliant on licensing and niche consumer-health products, exposing it to execution risk in scaling revenue fast enough to reach profitability before cash runs low.
What investors should watch next
Key near-term catalysts include the board's promised update to market guidance later in 2026, which should clarify expectations for the full FY26 year given the earlier warning that results would come in below prior expectations. Any trading update on cash position and Burn Rate will be closely scrutinised, as will progress in the search for a permanent chief executive following Rachel Parsonage's interim appointment.
Developments on the £0.7 million cost-recovery action against the former CEO, further details on internal control improvements from the new auditor relationship, and commercial newsflow - such as additional retail listings for AxisBiotix or Dermatonics, and licensing progress - will all help investors gauge whether the underlying Business can outrun the governance overhang.
Conclusion and outlook
(LSE:SBTX) SkinBioTherapeutics finds itself in an unusual position for a small-cap biotech: underlying commercial trading has been improving, with double-digit revenue growth and stable margins, even as the company works through the reputational and financial consequences of a former CEO's fabricated revenue disclosures.
For the shares to stabilise and re-rate, investors will likely need to see the cash burn brought under control, credible new guidance for FY26, and a sustained period without further governance surprises. Until then, the stock is likely to remain volatile and thinly traded, with the balance between genuine operational progress and balance-sheet and governance risk determining the next significant move. This article is for information purposes only and does not constitute Investment advice.






Please wait processing your request...